Konuma et al. [29] assessed the MRD status of 109 patients with MLL-r AML at pre-HSCT, with a probability of a 3-year OS of 39% in the MRD + cohort and 64% in the MRD- cohort (P = 0.02). The gene discussed is KMT2A; the disease is acute myeloid leukemia.